Skip to main content
S&P 5007,465.12-2.91%DOW52,379.96-1.83%NASDAQ24,572.21-4.52%BTC$76,325.00-4.96%ETH$2,277.10-6.17%GOLD$4,116.50+1.07%OIL$90.39+2.58%
Smart Investors Daily
SID Premium
HY

NASDAQ · HYPMY

Hypera S.A.

Healthcare · Drug Manufacturers - Specialty & Generic

$3.90

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 3:34 PM

SID Score

6.1/10

Composite research score

Smart Money

46/100

Neutral

Market cap
2.78B
P/E ratio
18.24
Dividend yield
5.28%
52-week range
— – —
Volume
7.2K
Avg. volume
9.02K

Price performance · HYPMY

HYPMY price history

1M range · 0 trading sessions · Daily adjusted prices

HYPMY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest HYPMY news

The latest Smart Investors Daily articles mentioning HYPMY.

Stock researchCompany · Overview

HYPMY research

Overview

Company profile and research snapshot.

Company profile

HYPERA SA S/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$5.32
Implied upside
—
Analysts
19
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Sep 21, 2026

Full Transcript: Hypera Q2 2026 Earnings Call

Hypera (OTC:HYPMY) released second-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time access to our

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By